Floatz logo

Durvalumab

Durvalumab

Chang Gung Memorial Hospitalmonoclonal_antibodyPhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Durvalumab cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Hui Bu
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
West China Hospital
Phase 2CCC
LENVATINIB
West China Hospital
Phase 2CCC
ETOPOSIDE
You Lu
Phase 2CCC
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Chang Gung Memorial Hospital
Phase 2CCC

View all 9 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →